نتایج جستجو برای: jak2

تعداد نتایج: 4657  

Journal: :Blood 2007
Alexandre Theocharides Marjorie Boissinot François Girodon Richard Garand Soon-Siong Teo Eric Lippert Pascaline Talmant Andre Tichelli Sylvie Hermouet Radek C Skoda

To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17 of 27 patients. Surprisingly, only 5 of 17 patients developed JAK2-V617F-positive AML, whereas 9 of 17 patients transformed to JAK2-V617F-negative AML. Microsat...

Journal: :American journal of physiology. Cell physiology 2014
Shefalee K Bhavsar Zohreh Hosseinzadeh Dirk Brenner Sabina Honisch Kashif Jilani Guoxing Liu Kalina Szteyn Mentor Sopjani Tak W Mak Ekaterina Shumilina Florian Lang

Janus kinase 2 (JAK2) contributes to intracellular signaling of leptin and erythropoietin, hormones protecting cells during energy depletion. The present study explores whether JAK2 is activated by energy depletion and regulates Na(+)/K(+)-ATPase, the major energy-consuming pump. In Jurkat cells, JAK2 activity was determined by radioactive kinase assay, phosphorylated JAK2 detected by Western b...

2016
Chia-Lung Tsai Angel Chao Shih-Ming Jung Chi-Neu Tsai Chiao-Yun Lin Shun-Hua Chen Shih-Che Sue Tzu-Hao Wang Hsin-Shih Wang Chyong-Huey Lai

Overexpression of stress-induced phosphoprotein 1 (STIP1) - a co-chaperone of heat shock protein (HSP) 70/HSP90 - and activation of the JAK2-STAT3 pathway occur in several tumors. Combined treatment with a HSP90 inhibitor and a JAK2 inhibitor exert synergistic anti-cancer effects. Here, we show that STIP1 stabilizes JAK2 protein in ovarian and endometrial cancer cells. Knock-down of endogenous ...

Journal: :Blood 2010
Franz X Schaub Renate Looser Sai Li Hui Hao-Shen Thomas Lehmann Andre Tichelli Radek C Skoda

Somatic mutations in TET2 occur in patients with myeloproliferative neoplasms and other hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and mutations in TET2 precede the acquisition of JAK2-V617F. To examine the order of events, we performed colony assays and genotyped TET2 and JAK2 in individual colonies. In 4 of 8 myeloproliferative neoplasm patients, we f...

2013
Sung O. Park Heather L. Wamsley Kyungmi Bae Zhongbo Hu Xiaomiao Li Se-woon Choe William B. Slayton S. Paul Oh Kay-Uwe Wagner Peter P. Sayeski

Germline deletion of Jak2 in mice results in embryonic lethality at E12.5 due to impaired hematopoiesis. However, the role that Jak2 might play in late gestation and postnatal life is unknown. To understand this, we utilized a conditional knockout approach that allowed for the deletion of Jak2 at various stages of prenatal and postnatal life. Specifically, Jak2 was deleted beginning at either m...

A Ghavamzadeh, A Zaghal, B Bahar, B Chahardouli, H Dargahi, K Alimoghaddam, N Einollahi, P Karimzadeh, SA Mousavi, SH Ghaffari,

Abstract Objective JAK2 is a non-receptor tyrosine kinase that plays a major role in myeloid disorders. JAK2V617F mutation is characterized by a G to T transverse at nucleotide 1849 in exon 12 of the JAK2 gene, located on the chromosome 9p, leading to a substitution of valine to phenylalanine at amino acid position 617 in the JAK2 protein. Methods In this study we evaluated RNA from 89 pati...

Journal: :Blood 2012
Mamta Gupta Jing Jing Han Mary Stenson Matthew Maurer Linda Wellik Guangzhen Hu Steve Ziesmer Ahmet Dogan Thomas E Witzig

Cytokines are deregulated in cancers and can contribute to tumor growth. In patients with diffuse large-cell lymphoma (DLBCL), we observed higher levels of JAK/STAT pathway-related serum cytokines (ie, IL-6, IL-10, epidermal growth factor, and IL-2) compared with controls. Of these, only IL-10 activated the JAK2 pathway in lymphoma cells in vitro. Patients with high serum IL-10 had shorter even...

Journal: :American journal of clinical pathology 2011
Jennifer Dunlap Katalin Kelemen Nicky Leeborg Rita Braziel Susan Olson Richard Press James Huang Ken Gatter Marc Loriaux Guang Fan

Myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms are heterogeneous disorders. JAK2 mutation testing and karyotyping are routinely used for diagnosis but have not been incorporated into risk stratification in Philadelphia chromosome-negative myeloproliferative neoplasms. This study correlated cytogenetic abnormalities with disease stage and JAK2 status. A total of 17...

2016
Roongrudee Singdong Teerapong Siriboonpiputtana Takol Chareonsirisuthigul Adcharee Kongruang Nittaya Limsuwanachot Tanasan Sirirat Suporn Chuncharunee Budsaba Rerkamnuaychoke

Background: The discovery of somatic acquired mutations of JAK2 (V617F) in Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) has not only improved rational disease classification and prognostication but also brings new understanding insight into the pathogenesis of diseases. Dos...

2016
Madeleine Themanns Kristina M. Mueller Sonja M. Kessler Nicole Golob-Schwarzl Thomas Mohr Doris Kaltenecker Jerome Bourgeais Jamile Paier-Pourani Katrin Friedbichler Doris Schneller Michaela Schlederer Eva Zebedin-Brandl Luigi M. Terracciano Xiaonan Han Lukas Kenner Kay-Uwe Wagner Wolfgang Mikulits Andrey V. Kozlov Markus H. Heim Fabrice Gouilleux Johannes Haybaeck Richard Moriggl

Genetic deletion of the tyrosine kinase JAK2 or the downstream transcription factor STAT5 in liver impairs growth hormone (GH) signalling and thereby promotes fatty liver disease. Hepatic STAT5 deficiency accelerates liver tumourigenesis in presence of high GH levels. To determine whether the upstream kinase JAK2 exerts similar functions, we crossed mice harbouring a hepatocyte-specific deletio...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید